APO RESEARCH · REPORT
Irritable Bowel Syndrome (IBS)
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
Product & engineering
Understand the product.
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
Selected research
Industry Research
Irritable Bowel Syndrome (IBS) Industry Research Report 2026
Market perspective
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
Report Scope
Read the full market overview
This report quantifies the global Irritable Bowel Syndrome (IBS) market in terms of revenue (US$ million) and, where applicable, service volume (Million Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Million Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Irritable Bowel Syndrome (IBS).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Irritable Bowel Syndrome (IBS) Market by Company
Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals
Irritable Bowel Syndrome (IBS) Segment by Type
IBS-D Drug
IBS-C Drug
Others
Irritable Bowel Syndrome (IBS) Segment by Application
Women
Men
Irritable Bowel Syndrome (IBS) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome (IBS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome (IBS) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome (IBS).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Irritable Bowel Syndrome (IBS) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- IBS-D Drug
- IBS-C Drug
- Others
Applications
- Women
- Men
Companies covered
- Bausch Health
- Allergan
- Takeda
- Sucampo Pharmaceuticals (Mallinckrodt)
- Sebela Pharmaceuticals Inc
- Astellas Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Irritable Bowel Syndrome (IBS) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 IBS-D Drug
- 2.2.3 IBS-C Drug
- 2.2.4 Others
- 2.3 Irritable Bowel Syndrome (IBS) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Women
- 2.3.3 Men
- 2.4 Assumptions and Limitations
3 Irritable Bowel Syndrome (IBS) Breakdown Data by Type
- 3.1 Global Irritable Bowel Syndrome (IBS) Historic Market Size by Type (2021-2026)
- 3.2 Global Irritable Bowel Syndrome (IBS) Forecasted Market Size by Type (2027-2032)
4 Irritable Bowel Syndrome (IBS) Breakdown Data by Application
- 4.1 Global Irritable Bowel Syndrome (IBS) Historic Market Size by Application (2021-2026)
- 4.2 Global Irritable Bowel Syndrome (IBS) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Irritable Bowel Syndrome (IBS) Market Perspective (2021-2032)
- 5.2 Global Irritable Bowel Syndrome (IBS) Growth Trends by Region
- 5.2.1 Global Irritable Bowel Syndrome (IBS) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Irritable Bowel Syndrome (IBS) Historic Market Size by Region (2021-2026)
- 5.2.3 Irritable Bowel Syndrome (IBS) Forecasted Market Size by Region (2027-2032)
- 5.3 Irritable Bowel Syndrome (IBS) Market Dynamics
- 5.3.1 Irritable Bowel Syndrome (IBS) Industry Trends
- 5.3.2 Irritable Bowel Syndrome (IBS) Market Drivers
- 5.3.3 Irritable Bowel Syndrome (IBS) Market Challenges
- 5.3.4 Irritable Bowel Syndrome (IBS) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Irritable Bowel Syndrome (IBS) Players by Revenue
- 6.1.1 Global Top Irritable Bowel Syndrome (IBS) Players by Revenue (2021-2026)
- 6.1.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Players (2021-2026)
- 6.2 Global Irritable Bowel Syndrome (IBS) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Irritable Bowel Syndrome (IBS) Head Office and Area Served
- 6.4 Global Irritable Bowel Syndrome (IBS) Players, Product Type & Application
- 6.5 Global Irritable Bowel Syndrome (IBS) Manufacturers Established Date
- 6.6 Global Irritable Bowel Syndrome (IBS) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Irritable Bowel Syndrome (IBS) Market Size (2021-2032)
- 7.2 North America Irritable Bowel Syndrome (IBS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Irritable Bowel Syndrome (IBS) Market Size by Country (2021-2026)
- 7.4 North America Irritable Bowel Syndrome (IBS) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Irritable Bowel Syndrome (IBS) Market Size (2021-2032)
- 8.2 Europe Irritable Bowel Syndrome (IBS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Irritable Bowel Syndrome (IBS) Market Size by Country (2021-2026)
- 8.4 Europe Irritable Bowel Syndrome (IBS) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Size (2021-2032)
- 9.2 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Irritable Bowel Syndrome (IBS) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Irritable Bowel Syndrome (IBS) Market Size (2021-2032)
- 10.2 South America Irritable Bowel Syndrome (IBS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Irritable Bowel Syndrome (IBS) Market Size by Country (2021-2026)
- 10.4 South America Irritable Bowel Syndrome (IBS) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Market Size (2021-2032)
- 11.2 Middle East & Africa Irritable Bowel Syndrome (IBS) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Irritable Bowel Syndrome (IBS) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Irritable Bowel Syndrome (IBS) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Bausch Health
- 12.1.1 Bausch Health Company Information
- 12.1.2 Bausch Health Business Overview
- 12.1.3 Bausch Health Revenue in Irritable Bowel Syndrome (IBS) Business (2021-2026)
- 12.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Product Portfolio
- 12.1.5 Bausch Health Recent Developments
- 12.2 Allergan
- 12.2.1 Allergan Company Information
- 12.2.2 Allergan Business Overview
- 12.2.3 Allergan Revenue in Irritable Bowel Syndrome (IBS) Business (2021-2026)
- 12.2.4 Allergan Irritable Bowel Syndrome (IBS) Product Portfolio
- 12.2.5 Allergan Recent Developments
- 12.3 Takeda
- 12.3.1 Takeda Company Information
- 12.3.2 Takeda Business Overview
- 12.3.3 Takeda Revenue in Irritable Bowel Syndrome (IBS) Business (2021-2026)
- 12.3.4 Takeda Irritable Bowel Syndrome (IBS) Product Portfolio
- 12.3.5 Takeda Recent Developments
- 12.4 Sucampo Pharmaceuticals (Mallinckrodt)
- 12.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Company Information
- 12.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Business Overview
- 12.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Revenue in Irritable Bowel Syndrome (IBS) Business (2021-2026)
- 12.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Portfolio
- 12.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
- 12.5 Sebela Pharmaceuticals Inc
- 12.5.1 Sebela Pharmaceuticals Inc Company Information
- 12.5.2 Sebela Pharmaceuticals Inc Business Overview
- 12.5.3 Sebela Pharmaceuticals Inc Revenue in Irritable Bowel Syndrome (IBS) Business (2021-2026)
- 12.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Portfolio
- 12.5.5 Sebela Pharmaceuticals Inc Recent Developments
- 12.6 Astellas Pharmaceuticals
- 12.6.1 Astellas Pharmaceuticals Company Information
- 12.6.2 Astellas Pharmaceuticals Business Overview
- 12.6.3 Astellas Pharmaceuticals Revenue in Irritable Bowel Syndrome (IBS) Business (2021-2026)
- 12.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio
- 12.6.5 Astellas Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst